Still's Disease, Adult-Onset
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Swedish Orphan Biovitrumanakinra
BiocorpTadekinig alfa
Syneos HealthAPB-R3
Clinical Trials (3)
Total enrollment: 67 patients across 3 trials
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
Start: Sep 2017Est. completion: May 201913 patients
Phase 3Terminated
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Start: Feb 2015Est. completion: Jul 201623 patients
Phase 2Completed
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
Start: Mar 2023Est. completion: Dec 202331 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.